With high -tech medical care and medicines, obviously, there will be serious problems

The medical industry is feverishly. A few days after the collapsed sanctions, it became obvious: the Russians in the foreseeable perspective are unlikely to be able to receive a limited, but still affordable high -tech medical care. And this will happen the more inevitable, the sooner the malfunctions of imported consumables and components will affect the domestic market. The reserves of both after a few months are exhausted.

Patients on hemodialysis

The vital hemodialysis procedure (replacement renal therapy) in Russia on an ongoing basis is obtained by patients with chronic renal failure in the terminal stage. There are more than 50 thousand people. Even a two -week delay in the procedure threatens a severe sick death. There is no alternative therapy in order to prevent people with severe renal failure, except for dialysis, do not.

The market of equipment and consumables for them is provided by the two largest foreign companies: B.Braun Avitum and Fresenius Medical Care.

The organizers of dialysis help draw an extremely pessimistic picture.

• Firstly, in dialysis, the dependence on imported consumables is one hundred percent. Countries for the production of dialysis, filtering systems, highways, concentrates - Germany, Japan, USA. Inevitably, the exchange rate instantly affects purchase prices. In addition to the growth in the cost of consumables, it is expected to increase the prices for logistics, as well as for the maintenance of medical equipment and the purchase of components.

• Secondly, the tariffs of compulsory medical insurance have not been covered by the costs of medical organizations for a long time that conduct dialysis. All chronic problems - low tariffs that were not indexed, and typical situations when hospitals assisted, but they were not paid for them - they can only worsen. Already now, all tariffs should grow by about 25%so that the system does not collapse, and people do not begin to die.

In recent days, requests have appeared on the forums of people on dialysis on how to receive this assistance abroad if you have to hurry to leave their homeland.

Palliative patients

Almost all consumables that are used in the departure and maintenance of life of incurably sick people, imported production. From portable Ivl to diapers. People prefer the products of an imported manufacturer due to good quality, because if, for example, a catheter (and there are a lot of devices to ensure the life of such patients), it is necessary to change daily for months, and sometimes years, it is important that it is as non-equalmatical as possible. It is such quality that the foreign manufacturer stably guarantees.

In the hospice “House with a lighthouse” “New”, they replied that in the coming months, everything necessary for wards of children is available. The main problem is that

Due to the sharp growth of the exchange rate, new purchases will require significantly more money.

According to approximate estimates, 730 thousand palliative patients live in Russia.

Endoprosthetics and dentistry

According to experts,

The share of domestic endoprostheses used in the replacement of the hip joint does not exceed 10%.

Surgeons prefer to work with imported manufacturers because they not only provide high quality prosthesis itself, but also supply service with it with it and a detailed description of the technology of the operation itself.

The same service parameters provide suppliers of dental implants in dentistry.

So the forecasts in the accessibility and these operations for Russians are also pessimistic.

Medicines

Now the reserves of drugs in Russia for the main positions are designed for 1-3 months. If the supply of drugs of European manufacturers is stopped, then they will not be fully compensated by domestic production.

There are still Chinese pharmaceuticals, Indian and domestic generics, although they are definitely inferior in quality to original drugs.

An inevitable reduction in the assortment and the growth of the cost of drugs is expected. The price of purchased raw materials, materials, packaging will grow.

In addition, the state enshrines the limitation of prices for vital medical drugs (GNLP), but at the previous prices it will be impossible to sell goods in the coming weeks. This means that the state must in the near future to revise the pricing procedure and increase financing.

Significant stress and unknown are waiting for the market for cancer. This was reported by the Vademecum Meddindustry Journal. They also have a maximum vacation price, which, due to the jump in the exchange rate, has already become lower than the cost of the drug. If you urgently do not pour in subsidies, then the deficiency of these drugs is inevitable.

On March 1, 2022, the Russian government said that they prepared a draft document that temporarily prohibiting foreign companies to leave capital of Russian enterprises. “In the current sanctions situation, foreign entrepreneurs are forced to be guided not by economic factors, but to make decisions under political pressure. To enable business to make balanced decisions, a draft presidential decree on the introduction of temporary restrictions on exit from Russian assets has been prepared. We expect that those who invested in our country will be able to work in it further, ”said Prime Minister Mikhail Mishustin.

In Astrazeneca, Sanofi, Stada, Bayer, Gedeon Richter, they assured that they were taking all the necessary measures to ensure uninterrupted deliveries. In Astrazeneca, a special working group was created for this. Bayer said they do not plan to change the long -term strategy for business development in Russia.